Compare F5 Inc (FFIV) vs GSK plc (GSK) Price & Performance

F5 (FFIV) trades at $414.00, up 0.98% in the last session, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $3.09 billion in 2025, with a net income margin of 21.95%, while the company raised its annual revenue forecast on robust cybersecurity demand (Reuters, 2026-07-27). The stock is near resistance at $417, with RSI indicating mild overbought conditions.

The outlook remains positive due to consistent earnings outperformance and AI-driven security growth, but risks include high valuation multiples (P/E of 32.98) and competitive pressures. Analysts maintain a moderate buy consensus with a $430.43 price target, suggesting potential upside from current levels.

GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.

GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.